Download PDF
Semin Thromb Hemost 2020; 46(01): 017-025
DOI: 10.1055/s-0039-3402425
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Managing Preoperative Hemostasis in Patients with Inherited and Acquired Bleeding Disorders

Patrick Kyei Mensah
1   Haemostasis and Thombosis Unit, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
,
Sue Pavord
2   Department of Haematology, Oxford University Hospitals NHS FT, Oxford, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
30 December 2019 (online)

    Permissions and Reprints

Abstract

Inherited and acquired bleeding disorders pose significant hemostatic challenges for surgery. Patients at particular risk of bleeding include those with inherited bleeding disorders such as hemophilia, von Willebrand disease, and platelet function defects; those on antiplatelet agents or anticoagulants; and those with acquired conditions such as immune thrombocytopenic purpura, liver disease, or renal impairment. Each has its own specific challenges and close collaboration between the anesthetic, surgical, and hematology teams is crucial. Optimizing surgical hemostasis for patients at risk involves attention to detail, with careful preoperative planning, meticulous surgical technique, prompt identification of complications and judicious use of hemostatic agents and blood components. This article gives an overview of the bleeding risks involved and therapeutic options to overcome them.

Keywords

bleeding - hemostasis - hemophilia - von Willebrand disease - liver disease - renal failure - thrombocytopenia
 

  • References

  • 1 UKHCDO Annual Report 2017–2018. Available at: http://www.ukhcdo.org/wp-content/uploads/2019/04/2018_UKHCDO_Annual_Report_2017_18_Data.pdf . Accessed December 14, 2019
    PubMed
  • 2 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69 (02) 454-459
    CrossrefPubMedGoogle Scholar
  • 3 Escobar M, Maahs J, Hellman E. , et al. Multidisciplinary management of patients with haemophilia with inhibitors undergoing surgery in the United States: perspectives and best practices derived from experienced treatment centres. Haemophilia 2012; 18 (06) 971-981
    CrossrefPubMedGoogle Scholar
  • 4 Clinical and Laboratory Standards Institute. Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays and Molecular Hemostasis Assays: Approved Guideline. 5th ed. CLSI H21–A5, Wayne, PA: Clinical and Laboratory Standards Institute; 2008
    Google Scholar
  • 5 Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339 (04) 245-253
    CrossrefPubMedGoogle Scholar
  • 6 Rattray B, Nugent DJ, Young G. Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. Haemophilia 2006; 12 (05) 514-517
    CrossrefPubMedGoogle Scholar
  • 7 Tsoukas C, Eyster ME, Shingo S. , et al. Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy. Blood 2006; 107 (05) 1785-1790
    CrossrefPubMedGoogle Scholar
  • 8 Aryal KR, Wiseman D, Siriwardena AK, Bolton-Maggs PH, Hay CR, Hill J. General surgery in patients with a bleeding diathesis: how we do it. World J Surg 2011; 35 (12) 2603-2610
    CrossrefPubMedGoogle Scholar
  • 9 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9 (04) 418-435
    CrossrefPubMedGoogle Scholar
  • 10 Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey. Haemophilia 1996; 2 (01) 28-31
    CrossrefPubMedGoogle Scholar
  • 11 Dormandy KM. Pre-operative investigation and management during surgery of patients with bleeding disorders. Ann R Coll Surg Engl 1971; 48 (01) 26-27
    PubMedGoogle Scholar
  • 12 Hermans C, Altisent C, Batorova A. , et al; European Haemophilia Therapy Standardisation Board. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia 2009; 15 (03) 639-658
    CrossrefPubMedGoogle Scholar
  • 13 Mannucci PM. Desmopressin: a nontransfusional hemostatic agent. Annu Rev Med 1990; 41: 55-64
    CrossrefPubMedGoogle Scholar
  • 14 Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1977; 1 (8017): 869-872
    PubMedGoogle Scholar
  • 15 Dunn AL, Powers JR, Ribeiro MJ, Rickles FR, Abshire TC. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 2000; 6 (01) 11-14
    CrossrefPubMedGoogle Scholar
  • 16 Duthie R. Reconstructive surgery and joint replacement. In: The Management of Musculoskeletal Problems in the Haemophilias. Oxford: Oxford University Press; 1994: 191-215
    Google Scholar
  • 17 Dimichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12 (04) 352-362
    CrossrefPubMedGoogle Scholar
  • 18 Stine KC, Shrum D, Becton DL. Use of FEIBA for invasive or surgical procedures in patients with severe hemophilia A or B with inhibitors. J Pediatr Hematol Oncol 2007; 29 (04) 216-221
    CrossrefPubMedGoogle Scholar
  • 19 Rangarajan S, Yee TT, Wilde J. Experience of four UK comprehensive care centres using FEIBA® for surgeries in patients with inhibitors. Haemophilia 2011; 17 (01) 28-34
    CrossrefPubMedGoogle Scholar
  • 20 Obergfell A, Auvinen MK, Mathew P. Recombinant activated factor VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: a review of the literature. Haemophilia 2008; 14 (02) 233-241
    CrossrefPubMedGoogle Scholar
  • 21 Malkan UY, Aksu S. Combination of novoseven and feiba in hemophiliac patients with inhibitors. Open Med (Wars) 2018; 13: 618-621
    PubMedGoogle Scholar
  • 22 Kulkarni R. Comprehensive care of the patient with haemophilia and inhibitors undergoing surgery: practical aspects. Haemophilia 2013; 19 (01) 2-10
    PubMedGoogle Scholar
  • 23 Kruse-Jarres R, Callaghan MU, Croteau SE. , et al. Surgical experience in two multicenter, open-label phase 3 studies of emicizumab in persons with hemophilia A with inhibitors (HAVEN 1 and HAVEN 2). Blood 2017; 130 (Suppl. 01) 89
    CrossrefPubMedGoogle Scholar
  • 24 Sadler JE, Budde U, Eikenboom JCJ. , et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4 (10) 2103-2114
    CrossrefPubMedGoogle Scholar
  • 25 Manucci PM. , et al; Italian Association of Haemophilia Centres. Evidence-based recommendations on the treatment of von Willebrand's disease in Italy. Blood Transfus 2009; 7: 117-126
    PubMedGoogle Scholar
  • 26 Castaman G, Lethagen S, Federici AB. , et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008; 111 (07) 3531-3539
    CrossrefPubMedGoogle Scholar
  • 27 Peyvandi F, Bolton-Maggs PH, Batorova A, De Moerloose P. Rare bleeding disorders. Haemophilia 2012; 18 (Suppl. 04) 148-153
    CrossrefPubMedGoogle Scholar
  • 28 Chee YL, Crawford JC, Watson HG, Greaves M. ; British Committee for Standards in Haematology. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. Br J Haematol 2008; 140 (05) 496-504
    CrossrefPubMedGoogle Scholar
  • 29 Bolton-Maggs PHB. The rare coagulation disorders. Treatment of haemophilia 2006. Available at: http://www1.wfh.org/publication/files/pdf-1188.pdf . Accessed December 14, 2019
    PubMedGoogle Scholar
  • 30 Mensah PK, Gooding R. Surgery in patients with inherited bleeding disorders. Anaesthesia 2015; 70 (Suppl. 01) 112-120 , e39–e40
    PubMedGoogle Scholar
  • 31 George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990; 75 (07) 1383-1395
    CrossrefPubMedGoogle Scholar
  • 32 Nurden AT, Freson K, Seligsohn U. Inherited platelet disorders. Haemophilia 2012; 18 (Suppl. 04) 154-160
    CrossrefPubMedGoogle Scholar
  • 33 Santoro C, Rago A, Biondo F. , et al. Prevalence of allo-immunization anti-HLA and anti-integrin alphaIIbbeta3 in Glanzmann thrombasthenia patients. Haemophilia 2010; 16 (05) 805-812
    CrossrefPubMedGoogle Scholar
  • 34 Tripodi A, Salerno F, Chantarangkul V. , et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41 (03) 553-558
    CrossrefPubMedGoogle Scholar
  • 35 Segal JB, Dzik WH. ; Transfusion Medicine/Hemostasis Clinical Trials Network. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005; 45 (09) 1413-1425
    CrossrefPubMedGoogle Scholar
  • 36 Tripodi A, Chantarangkul V, Primignani M. , et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007; 46 (02) 520-527
    CrossrefPubMedGoogle Scholar
  • 37 Bellest L, Eschwège V, Poupon R, Chazouillères O, Robert A. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology 2007; 46 (02) 528-534
    CrossrefPubMedGoogle Scholar
  • 38 Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion 2014; 54 (05) 1389-1405 , quiz 1388
    CrossrefPubMedGoogle Scholar
  • 39 Kozek-Langenecker SA, Afshari A, Albaladejo P. , et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30 (06) 270-382
    CrossrefPubMedGoogle Scholar
  • 40 Lentschener C, Flaujac C, Ibrahim F. , et al. Assessment of haemostasis in patients with cirrhosis: relevance of the ROTEM tests? A prospective, cross-sectional study. Eur J Anaesthesiol 2016; 33 (02) 126-133
    CrossrefPubMedGoogle Scholar
  • 41 Gurusamy KS, Pissanou T, Pikhart H, Vaughan J, Burroughs AK, Davidson BR. Methods to decrease blood loss and transfusion requirements for liver transplantation. Cochrane Database Syst Rev 2011; 12 (12) CD009052
    PubMedGoogle Scholar
  • 42 Acedillo RR, Shah M, Devereaux PJ. , et al. The risk of perioperative bleeding in patients with chronic kidney disease: a systematic review and meta-analysis. Ann Surg 2013; 258 (06) 901-913
    CrossrefPubMedGoogle Scholar
  • 43 Kim JH, Baek CH, Min JY, Kim JS, Kim SB, Kim H. Desmopressin improves platelet function in uremic patients taking antiplatelet agents who require emergent invasive procedures. Ann Hematol 2015; 94 (09) 1457-1461
    CrossrefPubMedGoogle Scholar
  • 44 Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 2007; 3 (03) 138-153
    PubMedGoogle Scholar
  • 45 British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120 (04) 574-596
    CrossrefPubMedGoogle Scholar
  • 46 Provan D, Stasi R, Newland AC. , et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115 (02) 168-186
    CrossrefPubMedGoogle Scholar
  • 47 Taylor A, Westwood JP, Laskou F, McGuckin S, Scully M. Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond. Br J Haematol 2017; 177 (03) 475-480
    CrossrefPubMedGoogle Scholar
  • 48 Zaja F, Barcellini W, Cantoni S. , et al. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study. Am J Hematol 2016; 91 (05) E293-E295
    CrossrefPubMedGoogle Scholar
  • 49 Carr JM, Kruskall MS, Kaye JA, Robinson SH. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med 1986; 80 (06) 1051-1054
    CrossrefPubMedGoogle Scholar
  • 50 Mithoowani S, Gregory-Miller K, Goy J. , et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol 2016; 3 (10) e489-e496
    PubMedGoogle Scholar